Home > Industry Verticals > Featured > Oncolytic Virus Therapy Market

Last updated on: August 13, 2018   |  Available Format   

Global Oncolytic Virus Therapy Market – Size, Share and Forecasts (2018-2025)

Report Summary

Oncolytic Virus Therapy Market

  • The global oncolytic virus Therapy market was estimated to reach a market value of USD XX million by 2025. The global oncolytic virus market is growing at a steady rate in the forecasted period 2018-2025.
Growth factors of global oncolytic virus therapy market:
  • Advancements in treatments, increasing R&D spend by global pharma companies, and growing availability of treatments are some of the major factors driving the growth of the market
  • . High costs for treatments, moderate success rate of treatments, high risk of side effects, stringent regulations, and low success rate and high investment costs for the pharma companies are the major factors restraining the growth of the market.

Segmentation of the global market:

  • The clinical trial environment for oncolytic virus is in the phase of rapid growth. The global clinical trial phase has been dominated by the North America and Europe region accounting for around 75% of the clinical trials with most of the trials in Phase 1 stage.
  • By drug class, Talimogene laherparepvec dominates the market in 2017 and is estimated to dominate the market by the end of the forecasted period 2025. By geography, North America accounts for the largest market share while Asia-Pacific market is estimated to grow at a faster rate in the forecasted period.

The oncolytic virus therapy market is segmented into:

By Therapy type:

  • HSV-based Oncolytic Viruses
  • Adenoviruses-based Oncolytic Viruses
  • Vaccinia Virus-based Oncolytic Viruses
  • Vesicular Stomatitis Virus-based Oncolytic Viruses
  • Newcastle Disease Virus-based Oncolytic Viruses

By Drug Class

  • Onxy-15
  • Talimogene laherparepvec
  • Reolysin
  • RIGVIR
  • Others

By Application

  • Prostate Cancer
  • Melanoma
  • Ovarian Cancer
  • Breast Cancer
  • Others

Some of the major companies in global oncolytic virus therapeutics market include

  • Pfizer
  • Viralytics
  • Roche
  • Merck
  • Amgen, Oncolytics Biotech, Sillajen, Viralytics, and Merck accounts for majority of the clinical trials. The global oncolytic virus market is a fairly consolidated market with presence of moderate number of players in the industry. Acquisitions, and investments in R & D are the key strategy adopted by the major companies for increasing the company’s revenues and market share.
Recent developments in the oncolytic virus market:
  • Pfizer has partnered with Western Oncolytics to investigate novel oncolytic virus technology
  • Merck has agreed to buy virus based cancer drug from Viralytics for USD 394 million in 2018
Why purchase the report?

Visualize the composition of the oncolytic virus therapy market across each indication, in terms of type and applications, highlighting the key commercial assets and players.
Identify commercial opportunities in oncolytic virus therapy market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of the oncolytic virus therapy market – level 4/5 segmentation
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study
Product mapping in excel for the key oncolytic virus therapy market products of all major market players

Target Audience

Raw Material Suppliers/ Buyers
Product Suppliers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Research Professionals
Emerging Companies
Manufacturers

TABLE OF CONTENTS

1 Methodology and Scope

1.1 Research methodology
1.2 Scope of the Report

2. Headlines & Trends

2.1 Headlines
2.2 Key Trends & Developments

3. Industry Analysis

3.1 Market Drivers
3.2 Market Restraints
3.3 Porters Five Forces Analysis
3.3.1 Suppliers Power
3.3.2 Buyer Power
3.3.3 Industry Competition
3.3.4 Threat of new Entrant
3.3.5 Threat of Substitutes

4. Clinical Trial Analysis

4.1 By Age Group
4.1.1 Child
4.1.2 Adult
4.1.3 Senior
4.2 By Gender
4.2.1 Male
4.2.2 Female
4.3 By Study Phases
4.3.1 Early Phase
4.3.2 Phase 1
4.3.3 Phase 2
4.3.4 Phase 3
4.3.5 Phase 4
4.4 By Study Type
4.4.1 Interventional
4.4.2 Observational

5. Product Pipeline Analysis

6. Segmentation by Application

6.1 Prostate Cancer
6.2 Melanoma
6.3 Ovarian Cancer
6.4 Breast Cancer
6.5Others

7. Segmentation by Drug Class

7.1 Onxy-15
7.2 Talimogene laherparepvec
7.3 Reolysin
7.4 RIGVIR
7.5 Others

8. Segmentation by Therapy Type

8.1 HSV-based Oncolytic Viruses
8.2 Adenoviruses-based Oncolytic Viruses
8.3 Vaccinia Virus-based Oncolytic Viruses
8.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
8.5 Newcastle Disease Virus-based Oncolytic Viruses

9. Geographic Analysis

9.1 North America
9.1.1 United States
9.1.2 Canada
9.1.3 Mexico
9.1.4 Others
9.2 Europe
9.2.1 United Kingdom
9.2.2 Spain
9.2.3 Germany
9.2.4 France
9.2.5 Rest of Europe
9.3 Asia-Pacific
9.3.1 India
9.3.2 China
9.3.3 Australia
9.3.4 Japan
9.3.5 Rest of Asia-Pacific
9.4 South America
9.4.1 Brazil
9.4.2 Argentina
9.4.3 Rest of South America
9.5 Rest of the World

10. Competitive Landscape

10.1 Market Share Analysis
10.2 Company Benchmarking
10.3 Key Strategies Adopted by Major Companies

11. Company Profiles*

11.1 Amgen
11.2 Pfizer
11.3 Oncolytics Biotech
11.4 Viralytics
11.5 Transgene
11.6 AstraZeneca
11.7 Lee Pharma
11.8 Roche
11.9 Merck
11.10 SillaJen Inc
12. Appendix
12.1 Sources
12.2 List of Charts
12.3 Expert Panel Validation
12.4 Disclaimer
12.5 Contact Us

Have Queries??

| TALK TO EXPERT

Single UserSite UserEnterprise License
Clear